| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Top-line Data example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Top-line Data example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Top-line Data example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Dianthus Therapeutics, Inc.$97.6
-2.43 (-2.43%)
C 55Pipeline Score Overvalued Biotech · Commercial
Market Cap
4.73 B
EPS
-4.14
P/E Ratio
-
Value Trade
48.85 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
34.53 M
Operating CF
-28.86 M
Total Assets
1.25 B
Total Liabilities
45.57 M
Equity
1.20 B
D/E Ratio
12,345
3.46 %
Week
-5.49 %
1 Month
75.74 %
3 Month
114.11 %
6 Month
-52.79 %
5 Year
-65.13 %
All Time
Cash Data
Cash Position
1.11 B
Monthly Burn
9.62 M
Runway
113.5 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
842.64 K
52 Week Range
16.64 - 96.50
% held by Insiders
16.09 %
% held by Institutions
109.55 %
Enterprise Value
3.62 B
Total Shares
54.65 M
Short %
15.22 %
Float Shares
51.21 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dianthus Therapeutics, Inc.
334Total events
6Upcoming
68Tier-1 (high impact)
2018 – 2028Coverage
Upcoming catalysts 6
Event history 328
Q3 2026
◆Topline ReadoutLBL-047Clinical Data
Top-line results in healthy volunteers expected in 2H 2026
Healthy volunteerssource ↗
Q3 2026
◆Interim AnalysisClaseprubartTrial
Interim responder analysis of Phase 3 CAPTIVATE trial in CIDP expected in 2H 2026
Chronic Inflammatory Demyelinating Polyneuropathysource ↗
Q3 2026
◆Topline ReadoutClaseprubartClinical Data
Top-line results from Phase 2 MoMeNtum trial in MMN anticipated in 2H 2026
Multifocal Motor Neuropathy (MMN)source ↗
Jun 29, 2026
▲Trial InitiationClaseprubartTrial
Initiation of Phase 3 EMERGE trial of claseprubart in gMG
generalized Myasthenia Gravissource ↗
Jun 9, 2026
◆Oral PresentationPresentation
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 3, 2026
Jun 2026
●Trial InitiationClaseprubartTrial
Initiation of Phase 3 trial in generalized Myasthenia Gravis expected in mid-2026
generalized Myasthenia Gravissource ↗
Jun 2026
May 6, 2026
▲Orphan Drug DesignationClaseprubartDesignation
Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis
Myasthenia Gravissource ↗
May 6, 2026
●Quarterly UpdateCorporate
Reported Q1 2026 financial results with cash position of ~$1.2 billion
May 2026
▲Orphan Drug DesignationClaseprubartDesignation
Orphan Drug Designation granted by FDA for MG
Myasthenia Gravissource ↗
May 1, 2026
●Equity OfferingCorporate
Inducement grants of stock options to six new non-executive employees
Drug Pipeline Intelligence
C55
Pipeline Score $1.3B
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.3x
rNPV / MCap Top 83%
Small Cap (rank 156 of 911)
Percentile RankDianthus Therapeutics, Inc. carries a moderate pipeline score (55/100), with $2.0B risk-adjusted pipeline value, led by Claseprubart in Myasthenia Gravis, Generalized (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Claseprubart Small molecule | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | NCT06858579 | 60% | $1.0B | RECRUITING | 256 | AVERAGE | B (67) | Dec 31, 2030 | MODERATE_RISK | LOW Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Claseprubart Orphan | Generalized Myasthenia Gravis | Phase 2 | 2026-06-29 | Claseprubart 300mg/2mL Q2W S.C. demonstrated rapid, sustained, statistically significant and clinically meaningful improvements over placebo as measured by both MG-ADL and QMG, including at Week 1 and at Week 13. The claseprubart 300mg/2mL Q2W dose was also statistically significant and clinically meaningful across other key efficacy endpoints, including MSE, MGC and MG-QoL-15r. Read More | Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis Read More | |
Claseprubart Orphan | Generalized Myasthenia Gravis | Phase 2 | 2026-06-29 | Claseprubart 300mg/2mL Q2W S.C. demonstrated rapid, sustained, statistically significant and clinically meaningful improvements over placebo as measured by both MG-ADL and QMG, including at Week 1 and at Week 13. The claseprubart 300mg/2mL Q2W dose was also statistically significant and clinically meaningful across other key efficacy endpoints, including MSE, MGC and MG-QoL-15r. Read More | Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis Read More | |
Claseprubart Orphan | Generalized Myasthenia Gravis | Phase 2 | 2026-06-29 | Claseprubart 300mg/2mL Q2W S.C. demonstrated rapid, sustained, statistically significant and clinically meaningful improvements over placebo as measured by both MG-ADL and QMG, including at Week 1 and at Week 13. The claseprubart 300mg/2mL Q2W dose was also statistically significant and clinically meaningful across other key efficacy endpoints, including MSE, MGC and MG-QoL-15r. Read More | Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DNTH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DNTH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DNTHDianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics announced the granting of equity awards to five new non-executive employees as part of their employment inducement strategy. These grants, approved by the independent Compensation Committee, include stock options for a total of 58,000 shares with a 10-year term. The initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to enhance the company's talent pool.
Read more →DNTHDianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
Dianthus Therapeutics has launched the Phase 3 EMERGE trial for claseprubart in patients with generalized Myasthenia Gravis (gMG). This global, randomized, placebo-controlled study aims to evaluate the efficacy of claseprubart, following promising Phase 2 results. Top-line data is expected in the second half of 2028, further advancing the company's neuromuscular franchise.
Read more →DNTH▲ +7.4%on this news
Forward-looking statements Certain statements in this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, i
Dianthus is focusing on the development of two investigational autoimmune therapies, claseprubart and DNTH212, aiming to provide convenient self-administration options for patients. The company maintains a strong financial position, with expectations of positive clinical developments and trials intended for several conditions, including chronic inflammatory demyelinating polyneuropathy and myasthenia gravis. However, risks abound as the success of these therapies heavily depends on forthcoming clinical trial results and regulatory approvals. Future milestones include scheduled data releases from various studies throughout 2026, showing potential for best-in-disease efficacy.
Read more →DNTHDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Dianthus Therapeutics has announced the granting of equity awards to three new non-executive employees as part of their hiring process. These inducement grants, approved by the Compensation Committee, include non-qualified stock options for a total of 60,000 shares. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent.
Read more →DNTH▼ -8.8%on this newsshared move
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics announced the granting of equity awards to three new non-executive employees as part of their inducement strategy under Nasdaq Listing Rule 5635(c)(4). The grants consist of stock options for 60,000 shares with a 10-year term and specific vesting conditions. This move aims to enhance the company's capabilities in developing therapies for severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics to Participate in Two Investor Conferences
Dianthus Therapeutics will participate in two investor conferences in June 2026. Ryan Savitz, the EVP, CFO, and CBO, will engage in a fireside chat at the Jefferies Global Healthcare Conference, while CEO Marino Garcia will speak at the Goldman Sachs Annual Global Healthcare Conference. These events aim to enhance investor relations and showcase the company's commitment to developing therapies for severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Dianthus Therapeutics reported a pivotal early GO decision in its CAPTIVATE study for claseprubart, achieving 20 confirmed responders with fewer participants than planned. The company also received Orphan Drug Designation for claseprubart in Myasthenia Gravis and is on track to initiate a Phase 3 trial in mid-2026. Additionally, Dianthus is building a rheumatology franchise around its drug DNTH212, targeting Sjögren’s Disease, Systemic Lupus Erythematosus, and Dermatomyositis.
Read more →DNTHLBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
Dianthus Therapeutics has prioritized LBL-047 for clinical development in Sjögren's disease, systemic lupus erythematosus, and dermatomyositis. This bifunctional fusion protein aims to address autoimmune diseases by targeting both innate and adaptive immune systems. A Phase 1 study has begun, with results expected in the second half of 2026. The recent public offering provides significant funding for its development.
Read more →DNTHDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Dianthus Therapeutics has announced the granting of equity awards to six new non-executive employees as part of their inducement strategy under Nasdaq Listing Rule 5635(c)(4). The grants include stock options for a total of 135,000 shares, with specific vesting terms. This move is aimed at enhancing the company's workforce as it develops therapies for severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics, Inc. has announced the granting of equity awards under Nasdaq Listing Rule 5635(c)(4) to six newly-hired non-executive employees. These inducement grants include non-qualified stock options for a total of 135,000 shares with a set exercise price and vesting schedule. The grants were approved by the Company's independent Compensation Committee as part of its efforts to attract talent and enhance its workforce.
Read more →DNTHDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 6, 2026
Dianthus Therapeutics announced the granting of equity awards to eight new non-executive employees as part of its recruitment strategy. These inducement grants, approved by the independent Compensation Committee, include stock options for a total of 135,000 shares. The options are designed to vest over four years, supporting the company's goal of developing therapies for severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Dianthus Therapeutics, Inc. has successfully closed its upsized public offering, raising around $719 million through the sale of 8,470,989 shares of common stock. The offering included an additional 1,157,407 shares purchased by underwriters and pre-funded warrants. The proceeds will be allocated towards clinical development, commercial readiness, and general corporate purposes.
Read more →DNTHDianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
Dianthus Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 7,313,582 shares at $81.00 per share, raising approximately $625 million. The funds will be directed towards advancing clinical and preclinical development activities, as well as general corporate purposes. The offering is scheduled to close on March 12, 2026, pending customary closing conditions. Underwriters also have an option to purchase additional shares, reflecting strong investor interest.
Read more →DNTH▲ +21.5%on this news· ran to +33% by day 1shared move
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
Dianthus Therapeutics announced a GO decision for its Phase 3 CAPTIVATE trial of claseprubart in CIDP, achieving early success with 20 confirmed responders. The company also reported financial results for Q4 and FY 2025, highlighting a net loss of $162.3 million. With a strong cash position, Dianthus plans to advance its clinical trials for claseprubart and DNTH212, targeting severe autoimmune diseases.
Read more →DNTH▲ +21.5%on this news· ran to +33% by day 1shared move
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Dianthus Therapeutics announced an early GO decision in the Phase 3 CAPTIVATE trial for claseprubart in CIDP, achieving 20 confirmed responders from fewer than 40 participants. The company plans to maintain the 300mg dose and engage regulators to remove a higher dose from the trial. An independent review confirmed the decision, highlighting no serious adverse events.
Read more →DNTH▲ +21.5%on this news· ran to +33% by day 1shared move
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
Dianthus Therapeutics, Inc. has announced a proposed underwritten public offering of $400 million in common stock, with an additional $60 million option for underwriters. The funds raised will be allocated to advance clinical and preclinical development activities and other corporate purposes. The offering is contingent on market conditions and has no definitive timeline for completion. The company, which focuses on therapies for severe autoimmune diseases, is assisted by multiple financial institutions in this effort.
Read more →DNTH▲ +21.5%on this news· ran to +33% by day 1shared move
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Dianthus Therapeutics has announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial, focusing on the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with claseprubart. The event is scheduled for March 9, 2026, at 8:00 a.m. ET, highlighting the company's ongoing commitment to developing advanced therapies for autoimmune diseases. This communication emphasizes the importance of engaging investors during pivotal trial phases.
Read more →DNTH▲ +12%on this news· ran to +43% by day 3shared move
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 3, 2026
Dianthus Therapeutics announced the granting of equity awards to three newly-hired employees as part of an inducement to accept employment. The grants include non-qualified stock options for a total of 26,000 shares, with specific vesting terms. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to building its workforce.
Read more →DNTHDianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
Dianthus Therapeutics, a clinical-stage biotechnology firm, will participate in the TD Cowen 46th Annual Health Care Conference in Boston. CEO Marino Garcia is scheduled for an analyst-led fireside chat on March 3, 2026, and will also hold one-on-one meetings with investors. This event highlights the company's commitment to advancing treatments for severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Dianthus Therapeutics, a clinical-stage biotechnology company, will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York City. CEO Marino Garcia is scheduled for an analyst-led fireside chat and will hold one-on-one meetings with investors. The company aims to develop transformative therapies for severe autoimmune diseases.
Read more →DNTH▼ -7%on this news
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
Dianthus Therapeutics, a clinical-stage biotechnology company, will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Marino Garcia is scheduled to present a corporate overview on January 12, 2026, and will also host one-on-one meetings with investors. This event is an opportunity for the company to showcase its advancements in treating severe autoimmune diseases.
Read more →DNTH▲ +5.4%on this news
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
Dianthus Therapeutics, a clinical-stage biotech firm, will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida. CEO Marino Garcia is scheduled for a fireside chat on December 2, 2025, and will conduct one-on-one meetings with investors. The company aims to develop next-generation therapies for severe autoimmune diseases.
Read more →DNTH▲ +8%on this news
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Dianthus Therapeutics reported significant advancements in its clinical trials, particularly for claseprubart, which showed promising results in treating generalized myasthenia gravis. The company also announced an exclusive license for DNTH212 and improved its financial outlook with substantial cash reserves. Upcoming trials are set to begin in 2026, indicating a robust pipeline for autoimmune therapies.
Read more →DNTHDianthus Therapeutics to Participate in Four Investor Conferences During November
Dianthus Therapeutics, a clinical-stage biotech firm, announced its participation in four investor conferences in November. CEO Marino Garcia will engage in fireside chats and one-on-one meetings to discuss the company's innovative therapies aimed at treating severe autoimmune diseases. This initiative reflects the company's commitment to investor relations and transparency.
Read more →DNTHDianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
Dianthus Therapeutics presented promising Phase 2 data for claseprubart at the AANEM Annual Meeting, highlighting its potential in treating generalized Myasthenia Gravis. The data included new open-label extension results supporting a 300mg/2mL Q4W dosing strategy. A Phase 3 trial is planned to begin in 2026, featuring multiple treatment arms. The company aims to establish claseprubart as a leading therapy in autoimmune disorders.
Read more →DNTHDianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
Dianthus Therapeutics has entered an exclusive licensing agreement with Leads Biolabs for DNTH212, a bifunctional inhibitor targeting severe autoimmune diseases. The drug aims to reduce Type 1 interferon production and suppress B cell function, potentially offering improved clinical benefits. A Phase 1 study is set to begin in late 2025, with top-line results expected in mid-2026.
Read more →DNTH▼ -5.1%on this news
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
Dianthus Therapeutics announced that results from the Phase 2 MaGic trial of claseprubart for generalized Myasthenia Gravis will be presented at the AANEM Annual Meeting in October 2025. The company will also host a virtual forum to discuss new treatment strategies for MG. Claseprubart is designed to selectively inhibit the classical complement pathway, offering potential advantages for patients with severe autoimmune diseases. Additionally, Dianthus plans to initiate a Phase 3 trial in gMG in 2026, demonstrating ongoing commitment to this therapeutic area.
Read more →DNTHDianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Dianthus Therapeutics, Inc. has successfully closed an upsized public offering, raising approximately $288 million by selling 7,627,879 shares at $33.00 each. The offering included additional shares purchased by underwriters, reflecting significant investor interest. Proceeds will be utilized for advancing clinical development and general corporate purposes.
Read more →DNTH▲ +6.6%on this newsshared move
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
Dianthus Therapeutics, Inc. has announced the pricing of an upsized public offering of 6,487,879 shares at $33.00 per share, aiming to raise approximately $251 million. The proceeds will be used to advance the company's clinical development and for general corporate purposes. The offering is expected to close on September 11, 2025, pending customary conditions.
Read more →DNTH▲ +20%on this news· ran to +43% by day 3shared move
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
Dianthus Therapeutics announced positive results from the Phase 2 MaGic trial of Claseprubart (DNTH103) for generalized Myasthenia Gravis. Both 300mg and 600mg doses showed significant improvements in key efficacy measures, including MG-ADL and QMG scores, with a favorable safety profile. A Phase 3 trial is anticipated to start in 2026.
Read more →DNTH▲ +20%on this news· ran to +43% by day 3shared move
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
Dianthus Therapeutics, Inc. has announced a proposed underwritten public offering of $150 million in common stock and potentially pre-funded warrants. The company plans to use the proceeds to advance its preclinical and clinical development initiatives and for general corporate purposes. Jefferies, TD Cowen, Evercore ISI, and Stifel are handling the offering as joint book-running managers. The completion of this offering is subject to market conditions and other factors.
Read more →DNTH▲ +20%on this news· ran to +43% by day 3shared move
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
Dianthus Therapeutics has announced a conference call and webcast to discuss the results from the Phase 2 MaGic trial of their drug claseprubart (DNTH103) in treating generalized Myasthenia Gravis. The call is scheduled for September 8, 2025, at 8:00 a.m. EDT. This initiative underscores the company's commitment to transparency with investors regarding their clinical trial outcomes.
Read more →DNTH▼ -6.1%on this news
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 FINANCIAL RESULTS Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in Septembe
Dianthus Therapeutics highlighted recent achievements and reported its Q2 financial results, including strong cash reserves of $309.1 million that will fund operations until late 2027. The company is anticipating top-line results from its Phase 2 MaGic trial of claseprubart in generalized Myasthenia Gravis in September 2025, alongside ongoing trials for Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy. The CEO noted the multibillion-dollar market potential for therapies in gMG, as current treatment access remains low.
Read more →DNTHDianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
Dianthus Therapeutics, a clinical-stage biotechnology firm, has announced its participation in the Jefferies Global Healthcare Conference, set for June 5, 2025, where CEO Marino Garcia will engage in a fireside chat. The company, known for its focus on novel monoclonal antibodies to address severe autoimmune diseases, will also conduct one-on-one meetings with investors. A live webcast of the presentation will be available on the company's website, showcasing their commitment to transparency and investor communication.
Read more →DNTHDianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
Dianthus Therapeutics has appointed Dr. Simon Read to its Board of Directors, bringing over 30 years of biopharmaceutical leadership and scientific experience. Dr. Read's background includes founding Mariana Oncology and senior roles at significant pharmaceutical companies, which will contribute to Dianthus's ongoing clinical programs. The company anticipates Phase 2 results for DNTH103 in September, marking an exciting time for its development in serious autoimmune conditions. Additionally, Lonnie Moulder will transition off the board after serving during a key growth phase for the company.
Read more →DNTHDIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q1 FINANCIAL RESULTS Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG)s Top-line MaGic results anticip
Dianthus Therapeutics has completed enrollment in the Phase 2 MaGic trial for DNTH103, targeting generalized Myasthenia Gravis, with top-line results expected in September 2025. The company reported a strong cash position of $331.5 million, projected to fund operations into the second half of 2027. Moreover, ongoing trials for CIDP and MMN showcase DNTH103's potential across multiple indications, although increased R&D and operational costs resulted in a net loss for Q1 2025. The company remains optimistic about the drug’s market differentiation and upcoming clinical results.
Read more →DNTHDianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
Dianthus Therapeutics has completed patient enrollment for its Phase 2 MaGic trial of DNTH103, a monoclonal antibody targeting generalized Myasthenia Gravis (gMG). Exceeding its target enrollment of 60 patients, the trial aims to assess safety and tolerability alongside efficacy outcomes. Initial top-line results are anticipated in September 2025, which will be crucial for the drug's further development. DNTH103 is designed to be self-administered, potentially addressing significant unmet needs in gMG treatment.
Read more →DNTHDianthus Therapeutics to Participate in Two Upcoming Investor Events
Dianthus Therapeutics, a clinical-stage biotechnology company focused on antibody therapeutics for autoimmune diseases, announced participation in two upcoming investor events. CEO Marino Garcia will engage in a fireside chat at the Baird Biotech Discovery Series and present at the Bank of America 2025 Health Care Conference. These events will allow the company to showcase its efforts and strategic direction to potential investors.
Read more →DNTHDIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q4 AND FY 2024 FINANCIAL RESULTS Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'2
Dianthus Therapeutics has reported its financial results for Q4 and FY 2024, highlighting the ongoing Phase 2 MaGic trial of DNTH103 for generalized Myasthenia Gravis, with top-line results expected in the second half of 2025. Concurrently, the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy is underway, with an interim analysis anticipated in 2026. The company maintains a robust cash position of $357 million which supports its funding through 2027, despite reporting a significant net loss for the year.
Read more →DNTH▲ +14.6%on this news
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
Dianthus Therapeutics has appointed John C. King as Chief Commercial Officer, while welcoming Sujay Kango to its Board of Directors. King has extensive experience in launching biologics in the biotech industry, which will be crucial for advancing Dianthus' corporate and commercial strategy. The company is focused on DNTH103, aimed at treating severe autoimmune diseases, with key data readouts expected later this year. Together, these leadership appointments signal a strategic move towards enhancing Dianthus' market position in the biotechnology sector.
Read more →DNTH▼ -6.3%on this news
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
Dianthus Therapeutics, a clinical-stage biotech firm focused on antibody therapeutics for autoimmune diseases, has announced its participation in two upcoming investor conferences. CEO Marino Garcia will engage in a fireside chat and meetings at the TD Cowen 45th Annual Health Care Conference on March 5 in Boston. CFO Ryan Savitz will host one-on-one meetings at the Jefferies Biotech on the Bay Summit on March 12 in Miami. This participation signifies Dianthus's commitment to advancing its initiatives and connecting with potential investors.
Read more →DNTHDianthus Therapeutics to Webcast Presentations at Two Investor Conferences
Dianthus Therapeutics, a clinical-stage biotech firm, announced its participation in two key investor conferences in February 2025. CEO Marino Garcia will present at the Guggenheim SMID Cap Biotech Conference and the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company focuses on advancing next-generation antibody complement therapeutics for severe autoimmune diseases. Live webcasts of these presentations will be available on their website.
Read more →DNTHDianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Dianthus Therapeutics, a clinical-stage biotechnology company, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The CEO, Marino Garcia, will present an overview of the company on January 15, 2025, in San Francisco. This event underscores Dianthus's focus on developing novel therapeutics for severe autoimmune diseases. A live webcast of the presentation will be available on the company's website under the investors' section.
Read more →DNTH▼ -6%on this news
FORWARD-LOOKING STATEMENTS Certain statements in this presentation (“Presentation”), other than purely historical information, may constitute “forward-looking statements” within the meaning of
Dianthus Therapeutics, Inc. reports on its investigational monoclonal antibody DNTH103, which targets the complement pathway for treating conditions like generalized Myasthenia Gravis. The company anticipates positive Phase 2 results for DNTH103 in 2025 and 2026, supporting its potential as a self-administered treatment option. Furthermore, there are risks associated with the uncertain timelines and potential costs in the ongoing development and clinical trials of DNTH103.
Read more →DNTHDIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q3 FINANCIAL RESULTS Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
Dianthus Therapeutics has announced the initiation of a pivotal Phase 3 trial for DNTH103 targeting Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), expected to commence by the end of 2024. The company also reported its Q3 financial results, showcasing a cash position of approximately $343 million, which is projected to support its operations until the second half of 2027. In addition, two Phase 2 trials for DNTH103 in generalized Myasthenia Gravis and Multifocal Motor Neuropathy are underway, with results anticipated in 2025 and 2026, respectively. Overall, the company remains optimistic about the potential of DNTH103 to address significant unmet medical needs in these autoimmune conditions.
Read more →DNTHDianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Dianthus Therapeutics, a clinical-stage biotech firm, announced its participation in three upcoming healthcare investor conferences in November and December 2024. CEO Marino Garcia will present at key events, including the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference. The presentations aim to provide insights into the company's advancement in antibody complement therapeutics for severe autoimmune diseases.
Read more →DNTH▲ +8.3%on this news
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
Dianthus Therapeutics has announced two poster presentations for its investigational therapy DNTH103 at the 2024 AANEM Annual Meeting. DNTH103, a classical pathway inhibitor, is being developed for treating generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy. The presentations will showcase preclinical data demonstrating the drug's differentiated profile and competitive pharmacodynamic potency compared to existing treatments. DNTH103 promises a more convenient administration method and a potentially safer profile for patients.
Read more →DNTHDianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
Dianthus Therapeutics, a clinical-stage biotechnology company, announced its participation in three important healthcare investor conferences throughout September. CEO Marino Garcia will present at the Baird and Cantor conferences in New York City, as well as a virtual summit hosted by Stifel. These events aim to provide insights into the company's development of next-generation antibody therapies. Live webcasts of the presentations will be available for interested investors.
Read more →DNTHDIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 FINANCIAL RESULTS Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 IND for Phase 2 MoM
Dianthus Therapeutics reported its Q2 financial results, highlighting ongoing clinical trials for DNTH103 in several autoimmune conditions, including generalized Myasthenia Gravis. The Phase 2 MaGic trial is underway, with top-line results expected in the second half of 2025, alongside FDA-cleared trials for Multifocal Motor Neuropathy. Despite a reported net loss of $17.6 million, the company has a significant cash runway into 2027, which supports continued development of its pipeline. Dianthus remains focused on maintaining operational excellence and preparing for further trials in Chronic Inflammatory Demyelinating Polyneuropathy by late 2024.
Read more →DNTHDianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
Dianthus Therapeutics has announced two poster presentations for its investigational drug DNTH103 at the 10th Congress of the European Academy of Neurology. DNTH103 is a classical pathway inhibitor aimed at treating patients with generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy. The presentations will showcase preclinical and in vitro data that emphasize the drug's differentiated profile in specific disease models. The company aims for DNTH103 to be a leading treatment option, providing effective control with a potentially reduced risk of serious infections compared to existing therapies.
Read more →DNTH▲ +5%on this news
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
Dianthus Therapeutics has received FDA clearance to initiate a Phase 2 trial for DNTH103, targeting Multifocal Motor Neuropathy (MMN). The MoMeNtum trial aims to assess the safety and efficacy of DNTH103, focusing on a safer, self-administered treatment option for patients. Preliminary results are expected in the second half of 2026. This marks a significant advancement in developing effective therapies for MMN, addressing a notable unmet medical need.
Read more →DNTH▼ -6.6%on this news
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
Dianthus Therapeutics, a clinical-stage biotechnology company, will participate in the Jefferies Global Healthcare Conference on June 6, 2024. CEO Marino Garcia will provide a corporate overview during the event in New York. The company is focused on developing next-generation antibody complement therapeutics, and has recently initiated a Phase 2 trial for its investigational drug DNTH103, targeting conditions such as Myasthenia Gravis. Dianthus aims to expand its clinical trials into other neuromuscular diseases.
Read more →DNTHDIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q1 FINANCIAL RESULTS Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H'25 Building a neu
Dianthus Therapeutics reported recent business achievements and Q1 financial results, highlighting the ongoing Phase 2 MaGic trial for DNTH103 in generalized Myasthenia Gravis (gMG) with top-line results expected in the second half of 2025. The company also plans to initiate additional Phase 2 trials for Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy in 2024. Despite a strong cash position of $377 million bolstered by a recent $230 million PIPE financing, the company reported a net loss of $13.7 million for Q1 2024. The potential of DNTH103 as a leading treatment in the neuromuscular franchise persists amid rising research and development costs.
Read more →DNTHDianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
Dianthus Therapeutics, a clinical-stage biotechnology firm, will participate in the Bank of America Securities 2024 Health Care Conference, with CEO Marino Garcia presenting a corporate overview on May 14, 2024. The company is focused on developing innovative monoclonal antibodies specifically for severe autoimmune diseases. Dianthus has initiated a Phase 2 trial for DNTH103, a potential best-in-class therapy, and plans to expand its clinical trials into additional neuromuscular conditions this year.
Read more →DNTH▲ +9.1%on this news
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
Dianthus Therapeutics has announced an oral presentation for its investigational drug DNTH103 at the upcoming AAN Annual Meeting scheduled for April 13-18, 2024. This investigational treatment, targeting severe autoimmune diseases such as generalized Myasthenia Gravis, aims to offer a safer, low-volume alternative to current therapies. The presentation will highlight the therapy's preclinical data and previously released Phase 1 findings, indicating its potential as a best-in-class treatment option. Additionally, Dianthus plans to initiate further Phase 2 trials for DNTH103 in various neuromuscular conditions later this year.
Read more →DNTHDIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q4 AND FY2023 FINANCIAL RESULTS Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1'24 with top-line results anticipated in
Dianthus Therapeutics has reported its Q4 and FY2023 financial results, highlighting its cash position of $389 million and the initiation of the Phase 2 MaGic trial for generalized Myasthenia Gravis (gMG). The company aims to build a neuromuscular franchise around its investigational product, DNTH103, and is planning additional trials for related conditions. Despite a net loss increase and rising expenses, the company's successful PIPE financing shows strong market confidence in its potential.
Read more →DNTHDianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics, a clinical-stage biotech firm, announced an equity inducement grant to a newly-hired employee under Nasdaq Listing Rule 5635(c)(4). The grant includes a non-qualified stock option for 30,000 shares priced at $25.75, with a vesting schedule over four years. This move reflects the company's commitment to building its team and enhancing its capabilities in developing antibody complement therapeutics for severe autoimmune diseases.
Read more →DNTHDianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
Dianthus Therapeutics has begun the Phase 2 MaGic trial for DNTH103, targeting generalized Myasthenia Gravis (gMG) after receiving FDA clearance. This global study aims to evaluate the safety and efficacy of DNTH103, a potential best-in-class complement inhibitor designed for subcutaneous self-administration. Initial top-line results from this trial are expected in the second half of 2025. Additionally, Dianthus plans to expand clinical trials to other neuromuscular conditions in the near future.
Read more →DNTHDianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Dianthus Therapeutics, a clinical-stage biotechnology firm, announced its participation in the TD Cowen 44th Annual Health Care Conference, with CEO Marino Garcia presenting on March 4, 2024. The company is focused on developing innovative antibody complement therapeutics for severe autoimmune diseases. Notably, they are advancing their promising candidate, DNTH103, into three Phase 2 trials starting this year. However, challenges such as potential delays and uncertainties in clinical trial outcomes remain.
Read more →DNTHDianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference
Dianthus Therapeutics announced its participation in the Guggenheim 6th Annual Biotechnology Conference scheduled for February 7, 2024. The company's senior management will engage in a fireside chat, highlighting their focus on next-generation antibody complement therapeutics for severe autoimmune diseases. Dianthus is advancing its lead candidate, DNTH103, into three Phase 2 trials in 2024, targeting conditions such as Myasthenia Gravis and Multifocal Motor Neuropathy. However, the company faces risks typical for clinical-stage biotech firms, including uncertainties in trial outcomes and regulatory approval.
Read more →DNTH▲ +37.2%on this news· ran to +49% by day 3
Dianthus Therapeutics Announces $230 Million Private Placement NEW YORK and
Dianthus Therapeutics announced a $230 million private placement through a securities purchase agreement to finance its research and development initiatives. The PIPE financing involves contributions from both new and existing investors and is anticipated to close on January 24, 2024, pending customary conditions. Proceeds will be allocated towards advancing the company's pipeline of antibody therapeutics targeting severe autoimmune diseases. However, the completion of this financing and the progress of clinical trials are both subject to inherent risks and uncertainties.
Read more →DNTHto the Company's Current Report on Form 8-K filed with the SEC on
Dianthus Therapeutics, Inc. is progressing its lead program DNTH103, an investigational monoclonal antibody aimed at treating generalized Myasthenia Gravis, with Phase 2 trials set to begin in Q1 2024. The company has reported a favorable half-life and a potent classical pathway inhibition profile for DNTH103, anticipating results in 2025. Despite positive aspects, risks remain regarding the unpredictability of clinical outcomes and operational timelines, with cash resources projected to last through mid-2026.
Read more →DNTH▲ +10.1%on this news· ran to +25% by day 1
Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Dianthus Therapeutics, a clinical-stage biotechnology company, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. CEO Marino Garcia will provide a corporate overview, highlighting the company's commitment to developing antibody complement therapeutics for severe autoimmune diseases. Notably, Dianthus is advancing DNTH103 into three Phase 2 trials targeting various conditions. The company's participation in this conference underscores its strategic goals and development pipeline.
Read more →DNTH▲ +15.1%on this news· ran to +51% by day 1
INDEX TO FI NAN CIAL STATEMENTS In connection with the closing of the Merger (as defined below in Note 1) Dianthus Therapeutics, Inc. changed its name to Dianthus Therapeutics OpCo, Inc. on
Dianthus Therapeutics, Inc. has changed its name to Dianthus Therapeutics OpCo, Inc. following the closing of a merger on September 11, 2023. The independent auditor's report from Deloitte & Touche LLP highlights significant financial challenges, including substantial losses and negative cash flows. These factors raise doubts about the company's ability to sustain operations moving forward, as stated in their financial statements. The company has also outlined management's current plans in response to these uncertainties.
Read more →DNTHDianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer
Dianthus Therapeutics, a clinical-stage biotechnology company, announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. With over 20 years of experience in drug discovery, Dr. Stavenhagen will lead the company's research initiatives, particularly focusing on its promising antibody therapeutics aimed at severe autoimmune diseases. Alongside, Jennifer Davis Ruff has been named Vice President of Investor Relations, bringing her extensive experience in corporate communications to the team. Dianthus is set to initiate three Phase 2 clinical trials for its C1s inhibitor, DNTH103, in 2024.
Read more →DNTHto the Company's Form 8-K/A filed on
Dianthus Therapeutics announced significant achievements for Q3 2023, including a successful merger with Magenta Therapeutics and positive Phase 1 data for its lead drug candidate DNTH103. The company indicated that DNTH103, which targets severe autoimmune disorders, is on track to enter Phase 2 trials in 2024. Dianthus reported a strong financial position with over $189 million in cash but also noted a net loss of $14.8 million for the quarter. The advancements signal potential growth in the company's pipeline and increased investor interest.
Read more →DNTHDianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results
Dianthus Therapeutics has successfully initiated trading on the Nasdaq under the ticker DNTH, following its merger with Magenta Therapeutics. The company announced positive Phase 1 results for its lead candidate, DNTH103, which showcased effective classical complement pathway inhibition and a promising safety profile. Dianthus is set to advance DNTH103 into Phase 2 trials in 2024, starting with generalized Myasthenia Gravis, backed by a strong financial position of over $189 million. The firm aims to cater to multiple neuromuscular indications and potentially establish a new standard of care.
Read more →DNTHDianthus Therapeutics to Participate in Upcoming Investor Healthcare Conferences in November
Dianthus Therapeutics has announced that its senior management team will participate in several investor healthcare conferences throughout November. These conferences include notable events such as the Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference in New York City and the Jefferies 2023 London Healthcare Conference. The company's participation highlights its commitment to advancing its innovative antibody complement therapeutics and engaging with potential investors.
Read more →DNTHis a part for a more detailed description of the process for seeking Fast Track Designation or Orphan Drug Designation. General Risk Factors Dianthus estimates of market opportunity and forecasts of market growth may pro
Dianthus Therapeutics is facing significant operational and financial challenges as it seeks to navigate the biotechnology landscape. The company does not have any clinically approved products yet and has reported considerable net losses. Due to its limited operating history and lack of completed clinical trials, evaluating its potential success remains challenging. Moreover, the need for additional capital funding could further complicate its business operations and future prospects.
Read more →DNTHDianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH
Dianthus Therapeutics announced positive top-line Phase 1 data for its lead clinical program DNTH103, highlighting its potential as a best-in-class treatment for autoimmune disorders. The drug, which offers a self-administered injection every two weeks, demonstrated significant efficacy in classical pathway inhibition and a favorable safety profile. Dianthus is set to start multiple Phase 2 trials in neuromuscular conditions such as generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy in 2024. Additionally, the company has begun trading on Nasdaq as DNTH, supported by a strong financial position.
Read more →DNTHMagenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split The combined company will operate as Dianthus Therapeutics, Inc. with its common stock traded on Na
Magenta Therapeutics has completed its merger with Dianthus Therapeutics, transitioning to a new name, Dianthus Therapeutics, Inc. The merger follows stockholder approval and includes a reverse stock split of 1-for-16 to meet Nasdaq listing requirements. Shares will begin trading under the ticker symbol DNTH on September 12, 2023. This merger marks a significant step for both companies as they integrate into a single entity on the public market.
Read more →DNTHMagenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus portfolio of next-generation antibody complement
Magenta Therapeutics and Dianthus Therapeutics have announced a merger agreement to form a new Nasdaq-listed company named Dianthus Therapeutics, Inc. This merger aims to advance Dianthus's pipeline of next-generation complement therapeutics, specifically focusing on the investigational product DNTH103, currently in Phase 1 trials. With an expected $180 million in cash and equivalents post-merger, the combined entity plans to fund its lead program and other pipeline candidates through mid-2026. The transaction is projected to close in the third quarter of 2023, subject to shareholder approvals and customary conditions.
Read more →DNTHMagenta Therapeutics Adopts Limited Duration Stockholder Rights Plan Cambridge, MA
Magenta Therapeutics has adopted a limited duration stockholder rights plan to maximize shareholder value and ensure a fair strategic review process. This initiative aims to protect the company and its shareholders from potential takeovers while providing the board sufficient time for decision-making. All current and future shareholders will equally benefit from this plan, which includes various shareholder protections. The rights become exercisable upon certain ownership thresholds being met, indicating a focused approach to corporate governance.
Read more →DNTHMagenta Therapeutics to Explore Strategic Alternatives Cambridge, MA
Magenta Therapeutics has announced a cessation of its program developments as part of a comprehensive review to explore strategic alternatives. The review aims to maximize shareholder value and could involve various transactions such as mergers or acquisitions. However, the company has not set a timeline for this process, introducing uncertainty about future directions. Stakeholders are cautioned about the inherent risks associated with such strategies and market conditions.
Read more →DNTHMagenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety Cambridge, MA
Magenta Therapeutics has voluntarily paused its Phase 1/2 Dose-Escalation Clinical Trial for MGTA-117 following a Grade 5 Serious Adverse Event that resulted in a patient's death, potentially linked to the drug. The company reported this event to the FDA as a Suspected Unexpected Serious Adverse Reaction. In light of this incident, Magenta is evaluating available data and determining the next steps for the drug's development. This pause underscores the critical importance of patient safety in clinical trials.
Read more →DNTHMagenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities Plan to Dose Additional Participants in Cohor
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities Plan to Dose Additional Participants in Cohort 3 per Clinical Trial Protocol Cambridge, MA December 2
Read more →DNTHMagenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates MGTA-117 preliminary clinical results from 15 patients across three do
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical tr
Read more →DNTHMagenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell d
Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerabili
Read more →DNTHMagenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors Cambridge, MA
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors Cambridge, MA August 17, 2022 Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant t
Read more →DNTHMagenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions, rapid drug clearance and a favorable tol
Read more →DNTHMagenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights Clinical observations from preliminary data at the lowest dose of MGTA-1
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights Clinical observations from preliminary data at the lowest dose of MGTA-117 in a Phase 1/2 clinical trial indicate target binding,
Read more →DNTHMagenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway Encouraging early data and progress in MGTA-117 Phase 1/2 targeted conditioning clinical trial Prioritization of portfo
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Encouraging early data and progress in MGTA-117 Phase 1/2 targeted conditioning clinical trial Prioritization of portfolio spending allows for extension of cash runway into Q2 2024 CAMBRID
Read more →DNTHMagenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights First patient dosed in MGTA-117 targeted conditioning Phase 1/2 clinical trial; clinical data is expected in
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program First patient dosed in MGTA-117 targeted conditioning Phase 1/2 clinical trial; clinical data is expected in 2022 IND-enabling preclinical studies initiated for CD45 antibody-d
Read more →DNTHMagenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022 -- MGTA-117 Phase 1/2 clinical trial is open for enrollment for patients with relapsed/refractory acute myeloid leukemia and my
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022 -- MGTA-117 Phase 1/2 clinical trial is open for enrollment for patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes; clinical data expected in 2022 -
Read more →DNTHMagenta Therapeutics Reports Third Quarter Financial Results and Program Highlights Positive topline clinical data from all patients in an investigator-initiated Phase 2 clinical trial evaluating stem cell mobilization a
Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights Positive topline clinical data from all patients in an investigator-initiated Phase 2 clinical trial evaluating stem cell mobilization and transplant engraftment using MGTA-145 plus plerixafor
Read more →DNTHMagenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights Progress in addressing the FDA s recommendations regarding bioassay and dose escalations to clear the current clinical hold on t
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights Progress in addressing the FDA s recommendations regarding bioassay and dose escalations to clear the current clinical hold on the company s Investigational New Drug Application to init
Read more →DNTHMagenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors CAMBRIDGE, Mass. (BUSINESS WIRE)
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors CAMBRIDGE, Mass. (BUSINESS WIRE) May 12, 2021 Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of
Read more →DNTHMagenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights Two Phase 2 clinical trials underway to evaluate MGTA-145 plus plerixafor; initial mobilization, collection, engraftment and dise
Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights Two Phase 2 clinical trials underway to evaluate MGTA-145 plus plerixafor; initial mobilization, collection, engraftment and disease outcome data in Multiple Myeloma patients to be first
Read more →DNTHMagenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights Magenta s stem cell mobilization and targeted antibody-drug conjugate conditioning programs continue to advan
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Magenta s stem cell mobilization and targeted antibody-drug conjugate conditioning programs continue to advance, with four clinical trials ongoing or planned in 2021 Ended year
Read more →DNTHMagenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials MGTA-145: Three Phase 2 clinical trials ongoing or planned to evaluate MGTA-145,
Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials MGTA-145: Three Phase 2 clinical trials ongoing or planned to evaluate MGTA-145, a biologic used in combination with plerixafor to mobiliz
Read more →DNTHMagenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer
Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer CAMBRIDGE, Mass. November 9, 2020 Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more pati
Read more →DNTHMagenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results Magenta advanced its MGTA-145 mobilization program, with two Phase 2 trials to be initiated by end of 2020; the Company s MGTA-1
Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results Magenta advanced its MGTA-145 mobilization program, with two Phase 2 trials to be initiated by end of 2020; the Company s MGTA-117 conditioning program is on track to file an IND and gen
Read more →DNTHMagenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results Collaborations announced with AVROBIO and Beam Therapeutics to evaluate potential usage of MGTA-117 in conditioning patients in
Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results Collaborations announced with AVROBIO and Beam Therapeutics to evaluate potential usage of MGTA-117 in conditioning patients in gene therapy and gene editing settings, respectively MGT
Read more →DNTHMagenta Therapeutics Launches Proposed Public Offering CAMBRIDGE, Mass.--(BUSINESS WIRE)
Magenta Therapeutics Launches Proposed Public Offering CAMBRIDGE, Mass.--(BUSINESS WIRE)-- June 24, 2020 Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more pati
Read more →DNTHMagenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results MGTA-117 ADC clinical candidate for immune and blood system reset has demonstrated broad therapeutic index; on track for initial
Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results MGTA-117 ADC clinical candidate for immune and blood system reset has demonstrated broad therapeutic index; on track for initial clinical data in 2021 Announced research and clinical co
Read more →DNTHMagenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development
Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development CAMBRIDGE, Mass. - Apr. 17, 2020 - Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset t
Read more →DNTHMagenta Therapeutics Provides Business Update MGTA-117 conditioning ADC-based program on track for initial clinical data in 2021 MGTA-145 stem cell mobilization Phase 1 program met all safety and efficacy endpoints and e
Magenta Therapeutics Provides Business Update MGTA-117 conditioning ADC-based program on track for initial clinical data in 2021 MGTA-145 stem cell mobilization Phase 1 program met all safety and efficacy endpoints and enrollment is complete in renal pharmacokinetic study; p
Read more →DNTHMagenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights New MGTA-117 antibody-drug conjugate (ADC) clinical candidate for conditioning demonstrated broad therapeuti
Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business New MGTA-117 antibody-drug conjugate (ADC) clinical candidate for demonstrated broad therapeutic index in data highlighted in oral presentation at Transplant and Cellular Thera
Read more →DNTHMagenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals New MGTA-117 ADC clinical candidate for conditioning demonstrates broad therapeutic index; advancing
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones CAMBRIDGE, Mass. January 13th, 2020 - Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of im
Read more →DNTHMagenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights Early clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of cells in 11 of 12 healt
Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights Early clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of cells in 11 of 12 healthy volunteers; updated data to be presented at ASH Report
Read more →DNTHMagenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights Initiated Phase 1 study of MGTA-145 first-line mobilization therapy, enrollment on track for data presentation before end
Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights Initiated Phase 1 study of MGTA-145 first-line mobilization therapy, enrollment on track for data presentation before end of year Presented updated Phase 2 clinical data on MGTA-4
Read more →DNTHMagenta Therapeutics Appoints Anne McGeorge to Board of Directors
Magenta Therapeutics Appoints Anne McGeorge to Board of Directors CAMBRIDGE, Mass. June 24, 2019 - Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today
Read more →DNTHMagenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights Dosed first subjects in Phase 1 study of MGTA-145 first-line mobilization therapy Presented updated Phase 2 clinical data o
Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights Dosed first subjects in Phase 1 study of MGTA-145 first-line mobilization therapy Presented updated Phase 2 clinical data on MGTA-456 cell therapy in patients with inherited metabo
Read more →DNTHMagenta Therapeutics Launches Proposed Public Offering
Magenta Therapeutics Launches Proposed Public Offering CAMBRIDGE, Mass. April 29, 2019 Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announ
Read more →DNTHMagenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights Declared development candidate in first targeted conditioning program Phase 1 study for first-line stem cell
Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Declared development candidate in first targeted conditioning program Phase 1 study for first-line stem cell mobilization program to begin 1H19 Presented updated clinical data
Read more →DNTHForward-Looking Statements This presentation contains forward-looking statements and information. The use of words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "ta
Magenta Therapeutics January 2019 Forward-Looking Statements This presentation contains forward-looking statements and information. The use of words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "wil
Read more →DNTHEMPLOYMENT AGREEMENT This Employment Agreement ( Agreement ) is made by and between Magenta Therapeutics, Inc., a Delaware corporation (the Company ), and Jason Ryan (the Executive ), and is effective as of the first dat
EMPLOYMENT AGREEMENT This Employment Agreement ( Agreement ) is made by and between Magenta Therapeutics, Inc., a Delaware corporation (the Company ), and Jason Ryan (the Executive ), and is effective as of the first date of the Executive s employment with the Company (the Effe
Read more →DNTHMagenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results Nine clinical and preclinical abstracts accepted for presentation at American Society of Hematology (ASH) annual meeting C
Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results Nine clinical and preclinical abstracts accepted for presentation at American Society of Hematology (ASH) annual meeting Continued to strengthen robust intellectual property positi
Read more →DNTHMagenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results Transplanted first patient with MGTA-456 in Phase 2 study in inherited metabolic disorders Strengthened Board of Director
Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results Transplanted first patient with MGTA-456 in Phase 2 study in inherited metabolic Strengthened Board of Directors and Scientific Advisory Board Raised $52 million in oversubscribe
Read more →Competitive Position
How DNTH ranks across every disease it competes inCompetitive Position is a premium feature
See how DNTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial